Filter Results
Related Organization
- Biological and Environmental Systems Science Directorate
(26)
- Computing and Computational Sciences Directorate (38)
- Energy Science and Technology Directorate (223)
- Fusion and Fission Energy and Science Directorate (24)
- Information Technology Services Directorate (3)
- Isotope Science and Enrichment Directorate (7)
- National Security Sciences Directorate (20)
- Neutron Sciences Directorate (11)
- Physical Sciences Directorate (135)
- User Facilities (27)
Researcher
- Andrzej Nycz
- Chris Masuo
- Luke Meyer
- William Carter
- Alex Walters
- Brian Sanders
- Bruce Hannan
- Bruce Moyer
- Debjani Pal
- Gerald Tuskan
- Ilenne Del Valle Kessra
- Isaiah Dishner
- Jeff Foster
- Jeffrey Einkauf
- Jennifer M Pyles
- Jerry Parks
- John F Cahill
- Josh Michener
- Joshua Vaughan
- Justin Griswold
- Kuntal De
- Laetitia H Delmau
- Liangyu Qian
- Loren L Funk
- Luke Sadergaski
- Mike Zach
- Padhraic L Mulligan
- Paul Abraham
- Peter Wang
- Polad Shikhaliev
- Sandra Davern
- Theodore Visscher
- Vilmos Kertesz
- Vladislav N Sedov
- Xiaohan Yang
- Yacouba Diawara
- Yang Liu

Enzymes for synthesis of sequenced oligoamide triads and tetrads that can be polymerized into sequenced copolyamides.
Contact
To learn more about this technology, email partnerships@ornl.gov or call 865-574-1051.

Ruthenium is recovered from used nuclear fuel in an oxidizing environment by depositing the volatile RuO4 species onto a polymeric substrate.

ORNL has developed a large area thermal neutron detector based on 6LiF/ZnS(Ag) scintillator coupled with wavelength shifting fibers. The detector uses resistive charge divider-based position encoding.

Detection of gene expression in plants is critical for understanding the molecular basis of plant physiology and plant responses to drought, stress, climate change, microbes, insects and other factors.

Spherical powders applied to nuclear targetry for isotope production will allow for enhanced heat transfer properties, tailored thermal conductivity and minimize time required for target fabrication and post processing.

Direct-acting antivirals are needed to combat coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2).

Biocompatible nanoparticles have been developed that can trap and retain therapeutic radionuclides and their byproducts at the cancer site. This is important to maximize the therapeutic effect of this treatment and minimize associated side effects.

There is a critical need for new antiviral drugs for treating infections of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2).